Instrument Inactif

Autres langues OvaScience Inc Nasdaq

Actions

US69014Q1013

Recherche biotechnologique et médicale

Autres langues

10/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
29/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement
30/09/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer
23/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
16/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)
16/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
09/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference
07/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
02/07/21	Millendo Therapeutics : Amendment to Current Report (SEC Filing - 8-K/A)
01/07/21	Tempest Therapeutics : MILLENDO THERAPEUTICS, INC. Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K/A)
28/06/21	Millendo Therapeutics : Tempest Closes Merger with Millendo and Completes PIPE Financing (Form 8-K)
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index
25/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.
23/06/21	Millendo Therapeutics : Tempest and Millendo Announce Stockholder Approval of Merger (Form 8-K)
23/06/21	MILLENDO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
22/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals
11/06/21	MILLENDO THERAPEUTICS, INC. : Other Events (form 8-K)
13/05/21	MILLENDO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
08/04/21	MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ
29/03/21	MILLENDO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020